Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

NCT01022996 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Everolimus (RAD001)

Sponsor

Novartis Pharmaceuticals